Cellectar Biosciences, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.55 | $-0.57 | -3.6% | Miss |
| Q12026 FY2026 | $-1.35 | $-1.33 | +1.5% | Beat |
| Q42025 FY2025 | $-1.19 | $-0.53 | +55.5% | Beat |
Back to CLRB overview · CLRB holders · CLRB KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.